Induced Pluripotent Stem Cells Production Market - By Process (Manual, Automated), Product & Service (Consumables & Kits, Instruments, Service), Application (Drug Development & Discovery, Regenerative Medicine), End-use, & Global Forecast, 2024-2032

Induced Pluripotent Stem Cells Production Market - By Process (Manual, Automated), Product & Service (Consumables & Kits, Instruments, Service), Application (Drug Development & Discovery, Regenerative Medicine), End-use, & Global Forecast, 2024-2032

Induced Pluripotent Stem Cells Production Market Size

Induced Pluripotent Stem Cells Production Market size was valued USD 1.4 billion in 2023 and is estimated to expand at 9.8% CAGR from 2024 to 2032. The expanding field of drug discovery and development has fuelled the demand for iPSCs, as they provide a valuable platform for modelling diseases and testing potential treatments.
 

Also, the vast therapeutic potential of stem cell-based therapies, growing incidence of cancer/oncology, increasing capital investments for stem cell-based research, and multiple advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) are driving the market growth. For instance, according to the American Cancer Society, in 2023, it is anticipated that, approximately 1.9 million fresh cases of cancer will be diagnosed and around 609,820 deaths due to cancer in the U.S. Therefore, collaborative efforts between academic institutions, research organizations, and pharmaceutical companies will contribute to the expansion of iPSC therapeutic capabilities for such diseases, thereby fostering the market progress.
 

Induced pluripotent stem cells (iPSCs) production refers to the process of reprogramming differentiated cells into a pluripotent state. Pluripotent stem cells are cells that can differentiate into various cell types found in the human body. iPSCs are particularly significant because they share similar characteristics with embryonic stem cells, but they are derived without the need for the destruction of embryos.
 

COVID-19 Impact

The COVID-19 pandemic had positive impact on the induced pluripotent stem cells production market expansion. The heightened focus on medical research and the urgent need for advanced therapeutic solutions accelerated iPSCs research and development efforts. With a surge in funding and collaborative initiatives, the iPSCs production market witnessed increased innovation and efficiency. Researchers leveraged the iPSC technology to model and understand the virus, screen potential drug candidates, and develop personalized treatments. This renewed emphasis on regenerative medicine and cell therapy propelled the market forward.
 

Induced Pluripotent Stem Cells Production Market Trends

• The escalating prevalence of cancer has emerged as a prominent catalyst propelling the growth of the induced pluripotent stem cells (iPSC) production market.
   
• As cancer continues to afflict a growing number of individuals worldwide, the demand for innovative and personalized therapeutic solutions has intensified. For instance, Global Cancer Observatory (GLOBOCAN) predicted that cancer cases in India would increase to 2.08 million, accounting for a rise of 57.5% in 2040 from 2020. This rising incidence of cancer is expected to spur the research and development efforts, thereby driving the iPSC production market.
   
• Furthermore, induced pluripotent stem cells, with their ability to differentiate into various cell types, hold immense potential for regenerative medicine and drug discovery. Their capacity to be reprogrammed into specific tissues and organs makes iPSCs a valuable tool in treating a wide range of diseases, including degenerative disorders and injuries.
   

Induced Pluripotent Stem Cells Production Market Analysis

Based on process, the market is segmented into manual iPSC production process and automated iPSC production process. The manual iPSC production process segment is expected to lead the market, projecting revenue of USD 2.6 billion by 2032.
 

• The high segmental growth can be attributed to the inherent flexibility and precision offered by manual iPSC production, allowing researchers and scientists to tailor the process to specific requirements.
   
• Further, manual iPSC production is becoming increasingly favored for its ability to cater to diverse experimental needs, enabling the generation of high-quality induced pluripotent stem cells with enhanced control and adaptability.
   

Based on product & services, the induced pluripotent stem cells production market is classified into products and service. The product segment is further categorized into instruments/ devices, automated platforms, and consumables & kits. The consumables & kits segment dominated the market in 2023 and is anticipated to grow at a CAGR of 8.9% between 2024 – 2032.
 

• High market share can be attributed to the escalating adoption of iPSC technology across various scientific disciplines, including regenerative medicine and drug discovery, that is driving the demand of consumables & kits.
   
• Researchers and biotechnologists are increasingly relying on specialized consumables and kits to streamline the iPSC production process, to ensure high efficiency and reproducibility, thus driving the segment trends.
   

Based on application, the induced pluripotent stem cells production market is classified into drug development & discovery, regenerative medicine, toxicology studies, and other applications. The drug development & discovery segment dominated the market accounting for the largest revenue in USD 624.9 million in 2023.
 

• Rising technological advancements and the ability to generate patient-specific cells for drug testing has accelerated the pace of pharmaceutical research, leading to more targeted and efficient drug development processes.
   
• Also, increasing prevalence of several chronic diseases and cancer cases is driving the demand for effective therapies, and induced pluripotent stem cells are widely used for development of innovative treatment plans.
   
• For instance, in February 2022, EdiGene, Inc. and Neukio Biotherapeutics, a company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, signed a R&D collaboration to develop next-generation immune cell therapies. Such initiatives by market players is expected to increase the production capacity for treatment plans.
   

Based on end-use, the induced pluripotent stem cells production market is classified into research & academic institutes, pharmaceutical & biotechnology companies , and contract research organizations. The research & academic institutes segment dominated the market in 2023 with a market share of 49.2%.
 

• Rising interest and investments in stem cell therapy & research has spurred the establishment of numerous research and academic institutions dedicated to advancing iPSC technology. These institutes serve as hubs for cutting-edge research, fostering collaborations and driving innovation in the field, making them major end-users of induced pluripotent stem cells production technologies.
   

 In 2023, North America held a significant business share of 41.3% in the induced pluripotent stem cells production market and is anticipated to dominate the market throughout the forecast period.
 

• The region's dominance can be attributed to a robust infrastructure for biotechnology research and development, coupled with significant investments in healthcare and life sciences.
   
• Additionally, leading technological advancements, a strong regulatory framework, and strategic collaborations among key market players further contribute to North America's substantial presence in iPSC production market.
   

Induced Pluripotent Stem Cells Production Market Share

The induced pluripotent stem cells production industry is characterized by diverse players competing in the industry, leveraging their research capabilities and global presence. Strategic collaborations, product innovations, and regulatory compliance further strengthen their positions. The market is characterized by ongoing technological advancements and a focus on developing safer and more effective products and services, further intensifying the competitive dynamics in the healthcare sector.
 

Induced Pluripotent Stem Cells Production Market Companies

The prominent players operating in the induced pluripotent stem cells production industry is as mentioned below

• Lonza
• Axol Biosciences Ltd.
• Evotec SE
• Hitachi Ltd.
• Merck KGaA
• REPROCELLS, Inc.
• Fate Therapeutics
• Thermo Fisher Scientific, Inc.
• StemCellsFactory III
• Applied StemCells, Inc.
• Creative Biolabs
• Bio-Techne Corporation
   

Induced Pluripotent Stem Cells Production Industry News

• In September 2021, Bio-Techne lunched its new medium, ExCellerate iPSC expansion medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. This helped the company to widen its portfolio of products and services in iPSCs production.
   
• In November 2020, Lonza and FUJIFILM Cellular Dynamics signed an agreement to expand the availability and use of iPSC technology. Under the agreement, FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors. This helped Lonza to further widen the scope of their service offerings.
   

The induced pluripotent stem cells production market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Process, 2018 – 2032 (USD Million)

• Manual iPSC production process
• Automated iPSC production process

By Product & Service, 2018 – 2032 (USD Million)

• Products
• Consumables & kits
• Instruments/ devices
• Automated platforms 
• Service

By Application, 2018 – 2032 (USD Million)

• Drug development & discovery
• Regenerative medicine
• Toxicology studies
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Pharmaceutical & biotechnology companies
• Research & academic institutes
• Contract research organizations

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa